Allspring Global Investments
FATE icon

Allspring Global Investments’s Fate Therapeutics FATE Stock Holding History

Allspring Global Investments’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4,362
Closed -$16.3K – 2336
2023
Q4 		$16.3K Buy
+4,362
New +$10.3K ﹤0.01% 1981
2023
Q3 		– Sell
-3,322
Closed -$15.8K – 2819
2023
Q2 		$15.8K Buy
3,322
+1,709
+106% +$9.43K ﹤0.01% 2492
2023
Q1 		$9.19K Sell
1,613
-38,447
-96% -$232K ﹤0.01% 2602
2022
Q4 		$404K Sell
40,060
-208,559
-84% -$3.92M ﹤0.01% 1657
2022
Q3 		$5.57M Buy
248,619
+30,317
+14% +$876K 0.01% 949
2022
Q2 		$5.41M Sell
218,302
-22,025
-9% -$608K 0.01% 965
2022
Q1 		$9.32M Sell
240,327
-3,520
-1% -$136K 0.01% 904
2021
Q4 		$14.3M Buy
+243,847
New +$13.8M 0.02% 815

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Allspring Global Investments's FATE Position: Q1 2024 in Review

Allspring Global Investments sold out of Fate Therapeutics (FATE) in Q1 2024, closing a stake of 4,362 shares — an estimated $16.3K sold.

Allspring Global Investments first reported a position in FATE in Q4 2021 and held it in 8 quarters. The position peaked at $14.3M in Q4 2021. 167 funds tracked by Wall St. Rank hold FATE as of Q1 2024.

  • Allspring Global Investments reported no remaining Fate Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Allspring Global Investments sold 4,362 Fate Therapeutics shares in Q1 2024, an estimated $16.3K.
  • Allspring Global Investments first reported a position in Fate Therapeutics in Q4 2021 and held it in 8 quarters.
  • Allspring Global Investments's Fate Therapeutics position peaked at $14.3M in Q4 2021.
  • 167 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2024.

Based on Allspring Global Investments's 13F filing for Q1 2024, filed 18 Apr 2024.